COMPLETE KIT INCLUDEDbacteriostatic water, syringes, protocol and guide with every order

Certified by ISSCA in Peru and Colombia•ISSCA World Peptide ConferencePERU 2026•Certified by ISSCA in Peru and Colombia•ISSCA World Peptide ConferencePERU 2026•Certified by ISSCA in Peru and Colombia•ISSCA World Peptide ConferencePERU 2026•Certified by ISSCA in Peru and Colombia•ISSCA World Peptide ConferencePERU 2026•
BioPeptideX logoBioPeptideX
Back

Research guide · Recovery & Repair

IGF-1 LR3 — research protocol

Long-acting IGF-1 analog studied for tissue growth and recovery studies.

Evidence boundary

This guide summarizes study areas and sources associated with the compound. BioPeptideX does not convert experimental information into a clinical regimen or recommend an individual dose, frequency, route or duration.

Catalog presentations

100mcg1mg

Concentration table

Mathematical reference only; this is not a dosing recommendation.

Resulting concentration0.50 mg/mL
On a U-100 syringe · 1 unit contains0.005 mg

Research areas

  • Long R3 IGF-1 analog
  • Recovery studies
  • Cold-chain handled

Most-cited research protocols

Educational information based on research protocols and literature; it does not replace guidance from a healthcare professional.

IGF-1 LR3 is a synthetic, longer-acting analog of insulin-like growth factor 1, engineered for extended activity. It is sold as a research reagent only and has no FDA-approved human use.

DoseFrequencyDurationRoute
Subcutaneous (SubQ) - Assessment20 mcg/dayOnce dailyN/ASubcutaneous
Subcutaneous (SubQ) - Low range20-40 mcg/dayOnce dailyN/ASubcutaneous
Intramuscular (IM) - Low-moderate20-50 mcg/dayOnce dailyN/AIntramuscular
Intramuscular (IM) - Moderate-high50-100 mcg/dayOnce dailyN/AIntramuscular

Cycle: Most protocols cap on-time at 4-6 weeks with at least equal off-time before any subsequent cycle.

Benefits and research observations: Monitor fasting blood glucose and hypoglycemic symptoms daily in Week 1, and track resting weight, waist circumference, and fasting glucose trend in Weeks 2-3.

Handling and storage

Store unreconstituted product according to its label and maintain the cold chain where applicable. After any preparation, follow only validated instructions for the specific product and diluent. Do not use if packaging is damaged or the solution shows particles or unexpected changes.

Warnings

Do not use this page for self-diagnosis or self-medication. Pregnancy, breastfeeding, minors, cancer history, allergies, active disease and concurrent treatments require individual professional evaluation.

Published sources

  1. 1.Tomas FM, et al. J Endocrinol, 1993.
  2. 2.Walton PE, et al. Growth Regul, 1995.